Biogen's book value per share for the quarter that ended in Dec. 2023 was $102.14.
During the past 12 months, Biogen's average Book Value Per Share Growth Rate was 9.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biogen was 105.70% per year. The lowest was -33.90% per year. And the median was 13.40% per year.
Biogen's current price is $202.34. Its book value per share for the quarter that ended in Dec. 2023 was $102.14. Hence, today's PB Ratio of Biogen is 1.98.
During the past 13 years, the highest P/B Ratio of Biogen was 9.51. The lowest was 1.89. And the median was 4.66.
Good Sign:
Biogen Inc stock PB Ratio (=1.89) is close to 10-year low of 1.89
Biogen Book Value per Share Historical Data
The historical data trend for Biogen's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen PB Ratio Distribution
For the Drug Manufacturers industry and Healthcare sector, Biogen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biogen's PB Ratio falls into.
Biogen Book Value per Share Calculation
Biogen's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Biogen (NAS:BIIB) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Biogen Book Value per Share Related Terms
Thank you for viewing the detailed overview of Biogen's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIIB has been successfully added to your 